Corbus begins dosing in Phase II Resunab trial to treat cystic fibrosis

US-based drug development firm Corbus Pharmaceuticals (CRBP) has started dosing in the Phase II clinical trial of its investigational new oral drug Resunab to treat cystic fibrosis (CF).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news